Corvus Pharmaceuticals, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)

State Street Corp. disclosed a stake exceeding 5% in Corvus Pharmaceuticals Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000636). The filing signals that the institutional investor has crossed the key 5% beneficial ownership threshold, a level that typically draws scrutiny from investors tracking shareholder concentration. The exact number of shares and percentage held were not specified in the headline disclosure. The move matters because large index and custody banks like State Street often hold stakes on behalf of clients, so the disclosure may reflect passive or client-driven positioning rather than a strategic bet. What to watch next: the full 13G text for precise share counts and whether State Street's position represents active or passive ownership.